BioCentury | Mar 18, 2020
Finance

March 17 Quick Takes: Tempus, Circle, Immatics, Exuma, CFIUS

...existing shareholders dievini Hopp BioTech, AT Impf and Wellington Partners. Exuma raises $19M series B F1 Oncology Inc....
...fees, according to a note from Cooley. Hongjiang Li, Staff Writer Tempus Labs Inc. Circle Pharma Inc. Immatics Biotechnologies GmbH F1 Oncology Inc. Exuma...
BioCentury | Jun 19, 2019
Company News

Management tracks: Ultragenyx promotes Erik Harris; plus F-star, Arbutus, Maze and more

...Samuels was CFO of Vetsource (Portland, Ore.). Exuma develops and commercializes products and technology from F1 Oncology Inc....
BioCentury | Jan 13, 2017
Company News

BioAtla, F1 Oncology and SunTerra deal

...BioAtla granted F1 Oncology exclusive, worldwide rights to IP for adoptive cellular therapy preparations and cancer treatments...
...lower on-target, off-tumor toxicity than existing therapies. BioAtla will receive a majority, non-controlling stake in F1 Oncology...
...payments. F1 Oncology will retain rights outside of China, including Hong Kong and Macau, and Taiwan. F1 Oncology...
BioCentury | Jan 6, 2017
Financial News

F1 Oncology completes venture financing

...round from F1 BioVentures, Sinobioway Group and SunTerra Capital. F1 Oncology Inc. , West Palm Beach, Fla. Alicia Parker F1 Oncology Inc....
Items per page:
1 - 4 of 4
BioCentury | Mar 18, 2020
Finance

March 17 Quick Takes: Tempus, Circle, Immatics, Exuma, CFIUS

...existing shareholders dievini Hopp BioTech, AT Impf and Wellington Partners. Exuma raises $19M series B F1 Oncology Inc....
...fees, according to a note from Cooley. Hongjiang Li, Staff Writer Tempus Labs Inc. Circle Pharma Inc. Immatics Biotechnologies GmbH F1 Oncology Inc. Exuma...
BioCentury | Jun 19, 2019
Company News

Management tracks: Ultragenyx promotes Erik Harris; plus F-star, Arbutus, Maze and more

...Samuels was CFO of Vetsource (Portland, Ore.). Exuma develops and commercializes products and technology from F1 Oncology Inc....
BioCentury | Jan 13, 2017
Company News

BioAtla, F1 Oncology and SunTerra deal

...BioAtla granted F1 Oncology exclusive, worldwide rights to IP for adoptive cellular therapy preparations and cancer treatments...
...lower on-target, off-tumor toxicity than existing therapies. BioAtla will receive a majority, non-controlling stake in F1 Oncology...
...payments. F1 Oncology will retain rights outside of China, including Hong Kong and Macau, and Taiwan. F1 Oncology...
BioCentury | Jan 6, 2017
Financial News

F1 Oncology completes venture financing

...round from F1 BioVentures, Sinobioway Group and SunTerra Capital. F1 Oncology Inc. , West Palm Beach, Fla. Alicia Parker F1 Oncology Inc....
Items per page:
1 - 4 of 4